{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T06:37:31Z","timestamp":1792132651478,"version":"4.4.0"},"reference-count":76,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,2,23]],"date-time":"2024-02-23T00:00:00Z","timestamp":1708646400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,2,23]],"date-time":"2024-02-23T00:00:00Z","timestamp":1708646400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Divers"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1007\/s11030-024-10808-w","type":"journal-article","created":{"date-parts":[[2024,2,23]],"date-time":"2024-02-23T12:03:02Z","timestamp":1708689782000},"page":"4181-4197","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Multi-method computational evaluation of the inhibitors against leucine-rich repeat kinase 2 G2019S mutant for Parkinson's disease"],"prefix":"10.1007","volume":"28","author":[{"given":"Ahmed","family":"Elhadi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noman","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fusheng","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shijun","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,23]]},"reference":[{"issue":"1","key":"10808_CR1","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1002\/mds.28075","volume":"36","author":"EC Hirsch","year":"2021","unstructured":"Hirsch EC, Standaert DG (2021) Ten unsolved questions about neuroinflammation in Parkinson\u2019s disease. Mov Disord 36(1):16\u201324. https:\/\/doi.org\/10.1002\/mds.28075","journal-title":"Mov Disord"},{"issue":"12","key":"10808_CR2","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1097\/SMJ.0b013e318273a60d","volume":"105","author":"T Fritsch","year":"2012","unstructured":"Fritsch T, Smyth KA, Wallendal MS, Hyde T, Leo G, Geldmacher DS (2012) Parkinson disease: research update and clinical management. South Med J 105(12):650\u2013656. https:\/\/doi.org\/10.1097\/SMJ.0b013e318273a60d","journal-title":"South Med J"},{"issue":"13","key":"10808_CR3","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1002\/mds.25945","volume":"29","author":"T Pringsheim","year":"2014","unstructured":"Pringsheim T, Jette N, Frolkis A, Steeves TD (2014) The prevalence of Parkinson\u2019s disease: a systematic review and meta-analysis. Mov Disord 29(13):1583\u20131590. https:\/\/doi.org\/10.1002\/mds.25945","journal-title":"Mov Disord"},{"issue":"1","key":"10808_CR4","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1093\/bmb\/ldn013","volume":"86","author":"CA Davie","year":"2008","unstructured":"Davie CA (2008) A review of Parkinson\u2019s disease. Br Med Bull 86(1):109\u2013127. https:\/\/doi.org\/10.1093\/bmb\/ldn013","journal-title":"Br Med Bull"},{"key":"10808_CR5","unstructured":"World Health Organization (2022) Parkinson disease. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/parkinson-disease. Accessed 24 April 2023"},{"issue":"1","key":"10808_CR6","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1111\/ene.14108","volume":"27","author":"R Balestrino","year":"2020","unstructured":"Balestrino R, Schapira AHV (2020) Parkinson disease. Eur J Neurol 27(1):27\u201342. https:\/\/doi.org\/10.1111\/ene.14108","journal-title":"Eur J Neurol"},{"issue":"15","key":"10808_CR7","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1056\/NEJM199810083391506","volume":"339","author":"AE Lang","year":"1998","unstructured":"Lang AE, Lozano AM (1998) Parkinson\u2019s disease. First of two parts. N Engl J Med 339(15):1044\u20131053. https:\/\/doi.org\/10.1056\/NEJM199810083391506","journal-title":"N Engl J Med"},{"issue":"1","key":"10808_CR8","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a008888","volume":"2","author":"C Klein","year":"2012","unstructured":"Klein C, Westenberger A (2012) Genetics of Parkinson\u2019s disease. Cold Spring Harb Perspect Med 2(1):a008888. https:\/\/doi.org\/10.1101\/cshperspect.a008888","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10808_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.neulet.2019.134609","volume":"715","author":"W Chen","year":"2020","unstructured":"Chen W, Yan X, Lv H, Liu Y, He Z, Luo X (2020) Gender differences in prevalence of LRRK2-associated Parkinson disease: a meta-analysis of observational studies. Neurosci Lett 715:134609. https:\/\/doi.org\/10.1016\/j.neulet.2019.134609","journal-title":"Neurosci Lett"},{"issue":"11","key":"10808_CR10","doi-asserted-by":"publisher","DOI":"10.1136\/jmg.2005.035568","volume":"42","author":"S Goldwurm","year":"2005","unstructured":"Goldwurm S, Di Fonzo A, Simons EJ, Rohe CF, Zini M, Canesi M, Tesei S, Zecchinelli A, Antonini A, Mariani C, Meucci N, Sacilotto G, Sironi F, Salani G, Ferreira J, Chien HF, Fabrizio E, Vanacore N, Dalla Libera A, Stocchi F, Diroma C, Lamberti P, Sampaio C, Meco G, Barbosa E, Bertoli-Avella AM, Breedveld GJ, Oostra BA, Pezzoli G, Bonifati V (2005) The G6055A (G2019S) mutation in LRRK2 is frequent in both early and late onset Parkinson\u2019s disease and originates from a common ancestor. J Med Genet 42(11):e65. https:\/\/doi.org\/10.1136\/jmg.2005.035568","journal-title":"J Med Genet"},{"issue":"5\u20136","key":"10808_CR11","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1159\/000488938","volume":"79","author":"J Chen","year":"2018","unstructured":"Chen J, Chen Y, Pu J (2018) Leucine-rich repeat kinase 2 in Parkinson\u2019s disease: updated from pathogenesis to potential therapeutic target. Eur Neurol 79(5\u20136):256\u2013265. https:\/\/doi.org\/10.1159\/000488938","journal-title":"Eur Neurol"},{"issue":"4","key":"10808_CR12","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.3892\/etm.2015.2659","volume":"10","author":"XX Li","year":"2015","unstructured":"Li XX, Liao Q, Xia H, Yang XL (2015) Association between Parkinson\u2019s disease and G2019S and R1441C mutations of the LRRK2 gene. Exp Ther Med 10(4):1450\u20131454. https:\/\/doi.org\/10.3892\/etm.2015.2659","journal-title":"Exp Ther Med"},{"key":"10808_CR13","doi-asserted-by":"publisher","first-page":"13","DOI":"10.3389\/fnagi.2019.00013","volume":"11","author":"L Shu","year":"2019","unstructured":"Shu L, Zhang Y, Sun Q, Pan H, Tang B (2019) A comprehensive analysis of population differences in LRRK2 variant distribution in Parkinson\u2019s disease. Front Aging Neurosci 11:13. https:\/\/doi.org\/10.3389\/fnagi.2019.00013","journal-title":"Front Aging Neurosci"},{"issue":"8","key":"10808_CR14","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1016\/j.bbadis.2013.11.005","volume":"1842","author":"M Verma","year":"2014","unstructured":"Verma M, Steer EK, Chu CT (2014) ERKed by LRRK2: a cell biological perspective on hereditary and sporadic Parkinson\u2019s disease. Biochim Biophys Acta 1842(8):1273\u20131281. https:\/\/doi.org\/10.1016\/j.bbadis.2013.11.005","journal-title":"Biochim Biophys Acta"},{"issue":"3","key":"10808_CR15","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0122461","volume":"10","author":"T Li","year":"2015","unstructured":"Li T, He X, Thomas JM, Yang D, Zhong S, Xue F, Smith WW (2015) A novel GTP-binding inhibitor, FX2149, attenuates LRRK2 toxicity in Parkinson\u2019s disease models. PLoS ONE 10(3):e0122461. https:\/\/doi.org\/10.1371\/journal.pone.0122461","journal-title":"PLoS ONE"},{"issue":"23","key":"10808_CR16","doi-asserted-by":"publisher","first-page":"6212","DOI":"10.1093\/hmg\/ddu341","volume":"23","author":"T Li","year":"2014","unstructured":"Li T, Yang D, Zhong S, Thomas JM, Xue F, Liu J, Kong L, Voulalas P, Hassan HE, Park JS, MacKerell AD Jr, Smith WW (2014) Novel LRRK2 GTP-binding inhibitors reduced degeneration in Parkinson\u2019s disease cell and mouse models. Hum Mol Genet 23(23):6212\u20136222. https:\/\/doi.org\/10.1093\/hmg\/ddu341","journal-title":"Hum Mol Genet"},{"issue":"45","key":"10808_CR17","doi-asserted-by":"publisher","first-page":"9700","DOI":"10.1523\/JNEUROSCI.1457-18.2018","volume":"38","author":"BA Matikainen-Ankney","year":"2018","unstructured":"Matikainen-Ankney BA, Kezunovic N, Menard C, Flanigan ME, Zhong Y, Russo SJ, Benson DL, Huntley GW (2018) Parkinson\u2019s disease-linked LRRK2-G2019S mutation alters synaptic plasticity and promotes resilience to chronic social stress in young adulthood. J Neurosci 38(45):9700\u20139711. https:\/\/doi.org\/10.1523\/JNEUROSCI.1457-18.2018","journal-title":"J Neurosci"},{"key":"10808_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2019.104614","volume":"134","author":"N Cresto","year":"2020","unstructured":"Cresto N, Gaillard MC, Gardier C, Gubinelli F, Diguet E, Bellet D, Legroux L, Mitja J, Auregan G, Guillermier M, Josephine C, Jan C, Dufour N, Joliot A, Hantraye P, Bonvento G, Deglon N, Bemelmans AP, Cambon K, Liot G, Brouillet E (2020) The C-terminal domain of LRRK2 with the G2019S mutation is sufficient to produce neurodegeneration of dopaminergic neurons in vivo. Neurobiol Dis 134:104614. https:\/\/doi.org\/10.1016\/j.nbd.2019.104614","journal-title":"Neurobiol Dis"},{"issue":"17","key":"10808_CR19","doi-asserted-by":"publisher","first-page":"4034","DOI":"10.1016\/j.bmcl.2017.07.052","volume":"27","author":"X Ding","year":"2017","unstructured":"Ding X, Dai X, Long K, Peng C, Andreotti D, Bamborough P, Eatherton AJ, Edge C, Jandu KS, Nichols PL, Philps OJ, Stasi LP, Wan Z, Xiang JN, Dong K, Dossang P, Ho MH, Li Y, Mensah L, Guan X, Reith AD, Ren F (2017) Discovery of 5-substituent-N-arylbenzamide derivatives as potent, selective and orally bioavailable LRRK2 inhibitors. Bioorg Med Chem Lett 27(17):4034\u20134038. https:\/\/doi.org\/10.1016\/j.bmcl.2017.07.052","journal-title":"Bioorg Med Chem Lett"},{"issue":"17","key":"10808_CR20","doi-asserted-by":"publisher","first-page":"4132","DOI":"10.1016\/j.bmcl.2014.07.052","volume":"24","author":"P Galatsis","year":"2014","unstructured":"Galatsis P, Henderson JL, Kormos BL, Han S, Kurumbail RG, Wager TT, Verhoest PR, Noell GS, Chen Y, Needle E, Berger Z, Steyn SJ, Houle C, Hirst WD (2014) Kinase domain inhibition of leucine rich repeat kinase 2 (LRRK2) using a [1, 2, 4]triazolo[4, 3-b]pyridazine scaffold. Bioorg Med Chem Lett 24(17):4132\u20134140. https:\/\/doi.org\/10.1016\/j.bmcl.2014.07.052","journal-title":"Bioorg Med Chem Lett"},{"issue":"11","key":"10808_CR21","doi-asserted-by":"publisher","first-page":"2631","DOI":"10.1016\/j.bmcl.2016.04.021","volume":"26","author":"TJ Greshock","year":"2016","unstructured":"Greshock TJ, Sanders JM, Drolet RE, Rajapakse HA, Chang RK, Kim B, Rada VL, Tiscia HE, Su H, Lai MT, Sur SM, Sanchez RI, Bilodeau MT, Renger JJ, Kern JT, McCauley JA (2016) Potent, selective and orally bioavailable leucine-rich repeat kinase 2 (LRRK2) inhibitors. Bioorg Med Chem Lett 26(11):2631\u20132635. https:\/\/doi.org\/10.1016\/j.bmcl.2016.04.021","journal-title":"Bioorg Med Chem Lett"},{"issue":"1","key":"10808_CR22","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1021\/jm5014055","volume":"58","author":"JL Henderson","year":"2015","unstructured":"Henderson JL, Kormos BL, Hayward MM, Coffman KJ, Jasti J, Kurumbail RG, Wager TT, Verhoest PR, Noell GS, Chen Y, Needle E, Berger Z, Steyn SJ, Houle C, Hirst WD, Galatsis P (2015) Discovery and preclinical profiling of 3-[4-(morpholin-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]benzonitrile (PF-06447475), a highly potent, selective, brain penetrant, and in vivo active LRRK2 kinase inhibitor. J Med Chem 58(1):419\u2013432. https:\/\/doi.org\/10.1021\/jm5014055","journal-title":"J Med Chem"},{"key":"10808_CR23","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1016\/j.ejmech.2017.06.060","volume":"138","author":"IG Salado","year":"2017","unstructured":"Salado IG, Zaldivar-Diez J, Sebastian-Perez V, Li L, Geiger L, Gonzalez S, Campillo NE, Gil C, Morales AV, Perez DI, Martinez A (2017) Leucine rich repeat kinase 2 (LRRK2) inhibitors based on indolinone scaffold: potential pro-neurogenic agents. Eur J Med Chem 138:328\u2013342. https:\/\/doi.org\/10.1016\/j.ejmech.2017.06.060","journal-title":"Eur J Med Chem"},{"issue":"7","key":"10808_CR24","doi-asserted-by":"publisher","first-page":"2983","DOI":"10.1021\/acs.jmedchem.7b00045","volume":"60","author":"JD Scott","year":"2017","unstructured":"Scott JD, DeMong DE, Greshock TJ, Basu K, Dai X, Harris J, Hruza A, Li SW, Lin SI, Liu H, Macala MK, Hu Z, Mei H, Zhang H, Walsh P, Poirier M, Shi ZC, Xiao L, Agnihotri G, Baptista MA, Columbus J, Fell MJ, Hyde LA, Kuvelkar R, Lin Y, Mirescu C, Morrow JA, Yin Z, Zhang X, Zhou X, Chang RK, Embrey MW, Sanders JM, Tiscia HE, Drolet RE, Kern JT, Sur SM, Renger JJ, Bilodeau MT, Kennedy ME, Parker EM, Stamford AW, Nargund R, McCauley JA, Miller MW (2017) Discovery of a 3-(4-pyrimidinyl) indazole (MLi-2), an orally available and selective leucine-rich repeat kinase 2 (LRRK2) inhibitor that reduces brain kinase activity. J Med Chem 60(7):2983\u20132992. https:\/\/doi.org\/10.1021\/acs.jmedchem.7b00045","journal-title":"J Med Chem"},{"issue":"18","key":"10808_CR25","doi-asserted-by":"publisher","first-page":"4500","DOI":"10.1016\/j.bmcl.2017.07.072","volume":"27","author":"GP Smith","year":"2017","unstructured":"Smith GP, Badolo L, Chell V, Chen IJ, Christensen KV, David L, Daechsel JA, Hentzer M, Herzig MC, Mikkelsen GK, Watson SP, Williamson DS (2017) The design and SAR of a novel series of 2-aminopyridine based LRRK2 inhibitors. Bioorg Med Chem Lett 27(18):4500\u20134505. https:\/\/doi.org\/10.1016\/j.bmcl.2017.07.072","journal-title":"Bioorg Med Chem Lett"},{"issue":"14","key":"10808_CR26","doi-asserted-by":"publisher","first-page":"4085","DOI":"10.1016\/j.bmcl.2013.05.054","volume":"23","author":"T Troxler","year":"2013","unstructured":"Troxler T, Greenidge P, Zimmermann K, Desrayaud S, Druckes P, Schweizer T, Stauffer D, Rovelli G, Shimshek DR (2013) Discovery of novel indolinone-based, potent, selective and brain penetrant inhibitors of LRRK2. Bioorg Med Chem Lett 23(14):4085\u20134090. https:\/\/doi.org\/10.1016\/j.bmcl.2013.05.054","journal-title":"Bioorg Med Chem Lett"},{"issue":"21","key":"10808_CR27","doi-asserted-by":"publisher","first-page":"8945","DOI":"10.1021\/acs.jmedchem.7b01186","volume":"60","author":"DS Williamson","year":"2017","unstructured":"Williamson DS, Smith GP, Acheson-Dossang P, Bedford ST, Chell V, Chen IJ, Daechsel JCA, Daniels Z, David L, Dokurno P, Hentzer M, Herzig MC, Hubbard RE, Moore JD, Murray JB, Newland S, Ray SC, Shaw T, Surgenor AE, Terry L, Thirstrup K, Wang Y, Christensen KV (2017) Design of leucine-rich repeat kinase 2 (LRRK2) inhibitors using a crystallographic surrogate derived from checkpoint kinase 1 (CHK1). J Med Chem 60(21):8945\u20138962. https:\/\/doi.org\/10.1021\/acs.jmedchem.7b01186","journal-title":"J Med Chem"},{"issue":"5","key":"10808_CR28","doi-asserted-by":"publisher","first-page":"1864","DOI":"10.1016\/j.bmcl.2012.01.084","volume":"22","author":"J Zhang","year":"2012","unstructured":"Zhang J, Deng X, Choi HG, Alessi DR, Gray NS (2012) Characterization of TAE684 as a potent LRRK2 kinase inhibitor. Bioorg Med Chem Lett 22(5):1864\u20131869. https:\/\/doi.org\/10.1016\/j.bmcl.2012.01.084","journal-title":"Bioorg Med Chem Lett"},{"issue":"6","key":"10808_CR29","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1021\/ci9800211","volume":"38","author":"P Willett","year":"1998","unstructured":"Willett P, Barnard JM, Downs GM (1998) Chemical similarity searching. J Chem Inf Comput Sci 38(6):983\u2013996. https:\/\/doi.org\/10.1021\/ci9800211","journal-title":"J Chem Inf Comput Sci"},{"issue":"1","key":"10808_CR30","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s13321-015-0069-3","volume":"7","author":"D Bajusz","year":"2015","unstructured":"Bajusz D, Racz A, Heberger K (2015) Why is Tanimoto index an appropriate choice for fingerprint-based similarity calculations? J Cheminform 7(1):20. https:\/\/doi.org\/10.1186\/s13321-015-0069-3","journal-title":"J Cheminform"},{"issue":"12","key":"10808_CR31","doi-asserted-by":"publisher","first-page":"2308","DOI":"10.1021\/ci800322y","volume":"48","author":"L Tan","year":"2008","unstructured":"Tan L, Lounkine E, Bajorath J (2008) Similarity searching using fingerprints of molecular fragments involved in protein\u2013ligand interactions. J Chem Inf Model 48(12):2308\u20132312. https:\/\/doi.org\/10.1021\/ci800322y","journal-title":"J Chem Inf Model"},{"key":"10808_CR32","doi-asserted-by":"publisher","DOI":"10.3390\/ph15050646","author":"D Giordano","year":"2022","unstructured":"Giordano D, Biancaniello C, Argenio MA, Facchiano A (2022) Drug design by pharmacophore and virtual screening approach. Pharmaceuticals (Basel). https:\/\/doi.org\/10.3390\/ph15050646","journal-title":"Pharmaceuticals (Basel)"},{"issue":"8","key":"10808_CR33","doi-asserted-by":"publisher","first-page":"2360","DOI":"10.1021\/acs.jcim.2c01623","volume":"63","author":"F Berenger","year":"2023","unstructured":"Berenger F, Tsuda K (2023) 3D-sensitive encoding of pharmacophore features. J Chem Inf Model 63(8):2360\u20132369. https:\/\/doi.org\/10.1021\/acs.jcim.2c01623","journal-title":"J Chem Inf Model"},{"issue":"2","key":"10808_CR34","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1109\/TCBB.2022.3172340","volume":"20","author":"C Tang","year":"2023","unstructured":"Tang C, Zhong C, Wang M, Zhou F (2023) FMGNN: A method to predict compound\u2013protein interaction with pharmacophore features and physicochemical properties of amino acids. IEEE\/ACM Trans Comput Biol Bioinform 20(2):1030\u20131040. https:\/\/doi.org\/10.1109\/TCBB.2022.3172340","journal-title":"IEEE\/ACM Trans Comput Biol Bioinform"},{"issue":"20","key":"10808_CR35","doi-asserted-by":"publisher","first-page":"4487","DOI":"10.1016\/j.bmcl.2015.08.080","volume":"25","author":"M Chen","year":"2015","unstructured":"Chen M, Yang X, Lai X, Gao Y (2015) 2D and 3D QSAR models for identifying diphenylpyridylethanamine based inhibitors against cholesteryl ester transfer protein. Bioorg Med Chem Lett 25(20):4487\u20134495. https:\/\/doi.org\/10.1016\/j.bmcl.2015.08.080","journal-title":"Bioorg Med Chem Lett"},{"issue":"2","key":"10808_CR36","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1080\/1062936X.2019.1695226","volume":"31","author":"V Kumar","year":"2020","unstructured":"Kumar V, Ojha PK, Saha A, Roy K (2020) Exploring 2D-QSAR for prediction of beta-secretase 1 (BACE1) inhibitory activity against Alzheimer\u2019s disease. SAR QSAR Environ Res 31(2):87\u2013133. https:\/\/doi.org\/10.1080\/1062936X.2019.1695226","journal-title":"SAR QSAR Environ Res"},{"issue":"5","key":"10808_CR37","doi-asserted-by":"publisher","first-page":"1978","DOI":"10.3390\/ijms10051978","volume":"10","author":"P Liu","year":"2009","unstructured":"Liu P, Long W (2009) Current mathematical methods used in QSAR\/QSPR studies. Int J Mol Sci 10(5):1978\u20131998. https:\/\/doi.org\/10.3390\/ijms10051978","journal-title":"Int J Mol Sci"},{"issue":"5","key":"10808_CR38","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1080\/1062936X.2016.1184713","volume":"27","author":"E Pourbasheer","year":"2016","unstructured":"Pourbasheer E, Aalizadeh R (2016) 3D-QSAR and molecular docking study of LRRK2 kinase inhibitors by CoMFA and CoMSIA methods. SAR QSAR Environ Res 27(5):385\u2013407. https:\/\/doi.org\/10.1080\/1062936X.2016.1184713","journal-title":"SAR QSAR Environ Res"},{"issue":"1","key":"10808_CR39","doi-asserted-by":"publisher","first-page":"20180063","DOI":"10.1515\/jib-2018-0063","volume":"16","author":"V Sebastian-Perez","year":"2019","unstructured":"Sebastian-Perez V, Martinez MJ, Gil C, Campillo NE, Martinez A, Ponzoni I (2019) QSAR modelling to identify LRRK2 inhibitors for Parkinson\u2019s disease. J Integr Bioinform 16(1):20180063. https:\/\/doi.org\/10.1515\/jib-2018-0063","journal-title":"J Integr Bioinform"},{"issue":"9","key":"10808_CR40","doi-asserted-by":"publisher","first-page":"3751","DOI":"10.1021\/jm5018779","volume":"58","author":"BK Gilsbach","year":"2015","unstructured":"Gilsbach BK, Messias AC, Ito G, Sattler M, Alessi DR, Wittinghofer A, Kortholt A (2015) Structural characterization of LRRK2 Inhibitors. J Med Chem 58(9):3751\u20133756. https:\/\/doi.org\/10.1021\/jm5018779","journal-title":"J Med Chem"},{"issue":"14","key":"10808_CR41","doi-asserted-by":"publisher","first-page":"10312","DOI":"10.1021\/acs.jmedchem.1c00720","volume":"64","author":"DS Williamson","year":"2021","unstructured":"Williamson DS, Smith GP, Mikkelsen GK, Jensen T, Acheson-Dossang P, Badolo L, Bedford ST, Chell V, Chen IJ, Dokurno P, Hentzer M, Newland S, Ray SC, Shaw T, Surgenor AE, Terry L, Wang Y, Christensen KV (2021) Design and synthesis of pyrrolo[2, 3-d]pyrimidine-derived leucine-rich repeat kinase 2 (LRRK2) inhibitors using a checkpoint kinase 1 (CHK1)-derived crystallographic surrogate. J Med Chem 64(14):10312\u201310332. https:\/\/doi.org\/10.1021\/acs.jmedchem.1c00720","journal-title":"J Med Chem"},{"issue":"7","key":"10808_CR42","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1039\/d1md00097g","volume":"12","author":"A Gulati","year":"2021","unstructured":"Gulati A, Yeung CS, Lapointe B, Kattar SD, Gunaydin H, Scott JD, Childers KK, Methot JL, Simov V, Kurukulasuriya R, Pio B, Morriello GJ, Liu P, Tang H, Neelamkavil S, Wood HB, Rada VL, Ardolino MJ, Yan XC, Palte R, Otte K, Faltus R, Woodhouse J, Hegde LG, Ciaccio P, Minnihan EC, DiMauro EF, Fell MJ, Fuller PH, Ellis JM (2021) Optimization of brain-penetrant picolinamide derived leucine-rich repeat kinase 2 (LRRK2) inhibitors. RSC Med Chem 12(7):1164\u20131173. https:\/\/doi.org\/10.1039\/d1md00097g","journal-title":"RSC Med Chem"},{"issue":"1","key":"10808_CR43","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1021\/acs.jmedchem.1c01968","volume":"65","author":"MH Keylor","year":"2022","unstructured":"Keylor MH, Gulati A, Kattar SD, Johnson RE, Chau RW, Margrey KA, Ardolino MJ, Zarate C, Poremba KE, Simov V, Morriello GJ, Acton JJ, Pio B, Yan X, Palte RL, McMinn SE, Nogle L, Lesburg CA, Adpressa D, Lin S, Neelamkavil S, Liu P, Su J, Hegde LG, Woodhouse JD, Faltus R, Xiong T, Ciaccio PJ, Piesvaux J, Otte KM, Wood HB, Kennedy ME, Bennett DJ, DiMauro EF, Fell MJ, Fuller PH (2022) Structure-guided discovery of aminoquinazolines as brain-penetrant and selective LRRK2 inhibitors. J Med Chem 65(1):838\u2013856. https:\/\/doi.org\/10.1021\/acs.jmedchem.1c01968","journal-title":"J Med Chem"},{"issue":"7","key":"10808_CR44","doi-asserted-by":"publisher","first-page":"13384","DOI":"10.3390\/molecules200713384","volume":"20","author":"LG Ferreira","year":"2015","unstructured":"Ferreira LG, Dos Santos RN, Oliva G, Andricopulo AD (2015) Molecular docking and structure-based drug design strategies. Molecules 20(7):13384\u201313421. https:\/\/doi.org\/10.3390\/molecules200713384","journal-title":"Molecules"},{"issue":"16","key":"10808_CR45","doi-asserted-by":"publisher","first-page":"9478","DOI":"10.1021\/acs.chemrev.9b00055","volume":"119","author":"E Wang","year":"2019","unstructured":"Wang E, Sun H, Wang J, Wang Z, Liu H, Zhang JZH, Hou T (2019) End-point binding free energy calculation with MM\/PBSA and MM\/GBSA: strategies and applications in drug design. Chem Rev 119(16):9478\u20139508. https:\/\/doi.org\/10.1021\/acs.chemrev.9b00055","journal-title":"Chem Rev"},{"issue":"11","key":"10808_CR46","doi-asserted-by":"publisher","first-page":"2520","DOI":"10.1016\/j.bmcl.2017.03.098","volume":"27","author":"E Gancia","year":"2017","unstructured":"Gancia E, De Groot M, Burton B, Clark DE (2017) Discovery of LRRK2 inhibitors by using an ensemble of virtual screening methods. Bioorg Med Chem Lett 27(11):2520\u20132527. https:\/\/doi.org\/10.1016\/j.bmcl.2017.03.098","journal-title":"Bioorg Med Chem Lett"},{"key":"10808_CR47","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.jtbi.2019.03.003","volume":"469","author":"AK Agrahari","year":"2019","unstructured":"Agrahari AK, Doss GPC, Siva R, Magesh R, Zayed H (2019) Molecular insights of the G2019S substitution in LRRK2 kinase domain associated with Parkinson\u2019s disease: a molecular dynamics simulation approach. J Theor Biol 469:163\u2013171. https:\/\/doi.org\/10.1016\/j.jtbi.2019.03.003","journal-title":"J Theor Biol"},{"key":"10808_CR48","doi-asserted-by":"publisher","DOI":"10.3390\/ijms232112825","author":"H Park","year":"2022","unstructured":"Park H, Kim T, Kim K, Jang A, Hong S (2022) Structure-based virtual screening and de novo design to identify submicromolar inhibitors of G2019S mutant of leucine-rich repeat kinase 2. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms232112825","journal-title":"Int J Mol Sci"},{"issue":"3","key":"10808_CR49","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1021\/acschemneuro.2c00672","volume":"14","author":"S Tan","year":"2023","unstructured":"Tan S, Lu R, Yao D, Wang J, Gao P, Xie G, Liu H, Yao X (2023) Identification of LRRK2 inhibitors through computational drug repurposing. ACS Chem Neurosci 14(3):481\u2013493. https:\/\/doi.org\/10.1021\/acschemneuro.2c00672","journal-title":"ACS Chem Neurosci"},{"issue":"1","key":"10808_CR50","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s13321-018-0258-y","volume":"10","author":"H Moriwaki","year":"2018","unstructured":"Moriwaki H, Tian YS, Kawashita N, Takagi T (2018) Mordred: a molecular descriptor calculator. J Cheminform 10(1):4. https:\/\/doi.org\/10.1186\/s13321-018-0258-y","journal-title":"J Cheminform"},{"issue":"7","key":"10808_CR51","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1002\/jcc.21707","volume":"32","author":"CW Yap","year":"2011","unstructured":"Yap CW (2011) PaDEL-descriptor: an open source software to calculate molecular descriptors and fingerprints. J Comput Chem 32(7):1466\u20131474. https:\/\/doi.org\/10.1002\/jcc.21707","journal-title":"J Comput Chem"},{"issue":"1","key":"10808_CR52","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s13321-015-0109-z","volume":"7","author":"J Dong","year":"2015","unstructured":"Dong J, Cao DS, Miao HY, Liu S, Deng BC, Yun YH, Wang NN, Lu AP, Zeng WB, Chen AF (2015) ChemDes: an integrated web-based platform for molecular descriptor and fingerprint computation. J Cheminform 7(1):60. https:\/\/doi.org\/10.1186\/s13321-015-0109-z","journal-title":"J Cheminform"},{"issue":"4","key":"10808_CR53","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1023\/a:1021372108686","volume":"5","author":"A Golbraikh","year":"2002","unstructured":"Golbraikh A, Tropsha A (2002) Predictive QSAR modeling based on diversity sampling of experimental datasets for the training and test set selection. Mol Divers 5(4):231\u2013243. https:\/\/doi.org\/10.1023\/a:1021372108686","journal-title":"Mol Divers"},{"issue":"3","key":"10808_CR54","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1002\/cem.1180020306","volume":"2","author":"A H\u00f6skuldsson","year":"1988","unstructured":"H\u00f6skuldsson A (1988) PLS regression methods. J Chemom 2(3):211\u2013228. https:\/\/doi.org\/10.1002\/cem.1180020306","journal-title":"J Chemom"},{"issue":"4","key":"10808_CR55","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/s1093-3263(01)00123-1","volume":"20","author":"A Golbraikh","year":"2002","unstructured":"Golbraikh A, Tropsha A (2002) Beware of q2! J Mol Graph Model 20(4):269\u2013276. https:\/\/doi.org\/10.1016\/s1093-3263(01)00123-1","journal-title":"J Mol Graph Model"},{"key":"10808_CR56","doi-asserted-by":"publisher","unstructured":"Kar S, Roy K, Leszczynski J (2018) Applicability domain: a step toward confident predictions and decidability for QSAR modeling. In: Computational toxicology. Springer, pp 141\u2013169. https:\/\/doi.org\/10.1007\/978-1-4939-7899-1_6","DOI":"10.1007\/978-1-4939-7899-1_6"},{"issue":"5","key":"10808_CR57","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1002\/qsar.200610151","volume":"26","author":"P Gramatica","year":"2007","unstructured":"Gramatica P (2007) Principles of QSAR models validation: internal and external. QSAR Comb Sci 26(5):694\u2013701. https:\/\/doi.org\/10.1002\/qsar.200610151","journal-title":"QSAR Comb Sci"},{"issue":"2","key":"10808_CR58","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1177\/026119290503300209","volume":"33","author":"TI Netzeva","year":"2005","unstructured":"Netzeva TI, Worth A, Aldenberg T, Benigni R, Cronin MT, Gramatica P, Jaworska JS, Kahn S, Klopman G, Marchant CA, Myatt G, Nikolova-Jeliazkova N, Patlewicz GY, Perkins R, Roberts D, Schultz T, Stanton DW, van de Sandt JJ, Tong W, Veith G, Yang C (2005) Current status of methods for defining the applicability domain of (quantitative) structure\u2013activity relationships. The report and recommendations of ECVAM Workshop 52. Altern Lab Anim 33(2):155\u2013173. https:\/\/doi.org\/10.1177\/026119290503300209","journal-title":"Altern Lab Anim"},{"issue":"2","key":"10808_CR59","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1002\/jcc.21334","volume":"31","author":"O Trott","year":"2010","unstructured":"Trott O, Olson AJ (2010) AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem 31(2):455\u2013461. https:\/\/doi.org\/10.1002\/jcc.21334","journal-title":"J Comput Chem"},{"issue":"11","key":"10808_CR60","doi-asserted-by":"publisher","first-page":"2493","DOI":"10.1016\/j.bmcl.2014.04.017","volume":"24","author":"H Zhao","year":"2014","unstructured":"Zhao H, Gartenmann L, Dong J, Spiliotopoulos D, Caflisch A (2014) Discovery of BRD4 bromodomain inhibitors by fragment-based high-throughput docking. Bioorg Med Chem Lett 24(11):2493\u20132496. https:\/\/doi.org\/10.1016\/j.bmcl.2014.04.017","journal-title":"Bioorg Med Chem Lett"},{"issue":"4","key":"10808_CR61","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.1007\/s11030-021-10323-2","volume":"26","author":"D Zhao","year":"2022","unstructured":"Zhao D, Sun L, Zhong S (2022) Discovery of inhibitors targeting protein tyrosine phosphatase 1B using a combined virtual screening approach. Mol Divers 26(4):2159\u20132174. https:\/\/doi.org\/10.1007\/s11030-021-10323-2","journal-title":"Mol Divers"},{"key":"10808_CR62","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23020811","author":"ME Bragina","year":"2022","unstructured":"Bragina ME, Daina A, Perez MAS, Michielin O, Zoete V (2022) The SwissSimilarity 2021 web tool: novel chemical libraries and additional methods for an enhanced ligand-based virtual screening experience. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms23020811","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10808_CR63","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1021\/ci049714+","volume":"45","author":"JJ Irwin","year":"2005","unstructured":"Irwin JJ, Shoichet BK (2005) ZINC\u2014a free database of commercially available compounds for virtual screening. J Chem Inf Model 45(1):177\u2013182. https:\/\/doi.org\/10.1021\/ci049714+","journal-title":"J Chem Inf Model"},{"issue":"Database issue","key":"10808_CR64","doi-asserted-by":"publisher","first-page":"D1100","DOI":"10.1093\/nar\/gkr777","volume":"40","author":"A Gaulton","year":"2012","unstructured":"Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP (2012) ChEMBL: a large-scale bioactivity database for drug discovery. Nucleic Acids Res 40(Database issue):D1100-1107. https:\/\/doi.org\/10.1093\/nar\/gkr777","journal-title":"Nucleic Acids Res"},{"issue":"6","key":"10808_CR65","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1147\/jrd.2018.2883977","volume":"62","author":"DR Koes","year":"2018","unstructured":"Koes DR (2018) The Pharmit backend: a computer systems approach to enabling interactive online drug discovery. IBM J Res Dev 62(6):1\u20136. https:\/\/doi.org\/10.1147\/jrd.2018.2883977","journal-title":"IBM J Res Dev"},{"issue":"3","key":"10808_CR66","first-page":"326","volume":"13","author":"S Zhong","year":"2010","unstructured":"Zhong S, Zhang Y, Xiu Z (2010) Rescoring ligand docking poses. Curr Opin Drug Discov Dev 13(3):326\u2013334","journal-title":"Curr Opin Drug Discov Dev"},{"key":"10808_CR67","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.softx.2015.06.001","volume":"1\u20132","author":"MJ Abraham","year":"2015","unstructured":"Abraham MJ, Murtola T, Schulz R, P\u00e1ll S, Smith JC, Hess B, Lindahl E (2015) GROMACS: high performance molecular simulations through multi-level parallelism from laptops to supercomputers. SoftwareX 1\u20132:19\u201325. https:\/\/doi.org\/10.1016\/j.softx.2015.06.001","journal-title":"SoftwareX"},{"issue":"1","key":"10808_CR68","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/nmeth.4067","volume":"14","author":"J Huang","year":"2017","unstructured":"Huang J, Rauscher S, Nawrocki G, Ran T, Feig M, de Groot BL, Grubm\u00fcller H, MacKerell AD (2017) CHARMM36m: an improved force field for folded and intrinsically disordered proteins. Nat Methods 14(1):71\u201373. https:\/\/doi.org\/10.1038\/nmeth.4067","journal-title":"Nat Methods"},{"issue":"4","key":"10808_CR69","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1002\/jcc.21367","volume":"31","author":"K Vanommeslaeghe","year":"2010","unstructured":"Vanommeslaeghe K, Hatcher E, Acharya C, Kundu S, Zhong S, Shim J, Darian E, Guvench O, Lopes P, Vorobyov I, Mackerell AD Jr (2010) CHARMM general force field: a force field for drug-like molecules compatible with the CHARMM all-atom additive biological force fields. J Comput Chem 31(4):671\u2013690. https:\/\/doi.org\/10.1002\/jcc.21367","journal-title":"J Comput Chem"},{"issue":"1","key":"10808_CR70","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1146\/annurev.physchem.51.1.129","volume":"51","author":"D Bashford","year":"2000","unstructured":"Bashford D, Case DA (2000) Generalized born models of macromolecular solvation effects. Annu Rev Phys Chem 51(1):129\u2013152. https:\/\/doi.org\/10.1146\/annurev.physchem.51.1.129","journal-title":"Annu Rev Phys Chem"},{"issue":"2","key":"10808_CR71","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1002\/prot.20033","volume":"55","author":"A Onufriev","year":"2004","unstructured":"Onufriev A, Bashford D, Case DA (2004) Exploring protein native states and large-scale conformational changes with a modified generalized born model. Proteins 55(2):383\u2013394. https:\/\/doi.org\/10.1002\/prot.20033","journal-title":"Proteins"},{"issue":"2","key":"10808_CR72","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1002\/(SICI)1096-987X(19990130)20:2<217::AID-JCC4>3.0.CO;2-A","volume":"20","author":"J Weiser","year":"1999","unstructured":"Weiser J, Shenkin PS, Still WC (1999) Approximate atomic surfaces from linear combinations of pairwise overlaps (LCPO). J Comput Chem 20(2):217\u2013230. https:\/\/doi.org\/10.1002\/(SICI)1096-987X(19990130)20:2%3c217::AID-JCC4%3e3.0.CO;2-A","journal-title":"J Comput Chem"},{"issue":"10","key":"10808_CR73","doi-asserted-by":"publisher","first-page":"6281","DOI":"10.1021\/acs.jctc.1c00645","volume":"17","author":"MS Valdes-Tresanco","year":"2021","unstructured":"Valdes-Tresanco MS, Valdes-Tresanco ME, Valiente PA, Moreno E (2021) gmx_MMPBSA: a new tool to perform end-state free energy calculations with GROMACS. J Chem Theory Comput 17(10):6281\u20136291. https:\/\/doi.org\/10.1021\/acs.jctc.1c00645","journal-title":"J Chem Theory Comput"},{"issue":"4","key":"10808_CR74","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1021\/ci8004429","volume":"49","author":"X Zhang","year":"2009","unstructured":"Zhang X, Li X, Wang R (2009) Interpretation of the binding affinities of PTP1B inhibitors with the MM-GB\/SA method and the X-score scoring function. J Chem Inf Model 49(4):1033\u20131048. https:\/\/doi.org\/10.1021\/ci8004429","journal-title":"J Chem Inf Model"},{"issue":"1","key":"10808_CR75","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1021\/ci100275a","volume":"51","author":"T Hou","year":"2011","unstructured":"Hou T, Wang J, Li Y, Wang W (2011) Assessing the performance of the MM\/PBSA and MM\/GBSA methods. 1. The accuracy of binding free energy calculations based on molecular dynamics simulations. J Chem Inf Model 51(1):69\u201382. https:\/\/doi.org\/10.1021\/ci100275a","journal-title":"J Chem Inf Model"},{"issue":"4","key":"10808_CR76","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1080\/08927022.2021.2015068","volume":"48","author":"L Sun","year":"2021","unstructured":"Sun L, Zhang C, Chen J, Zhao X, Bai F, Zhong S (2021) Combining oligomer build-up with alanine scanning to determine the flocculation protein mutants for enhancing oligosaccharide binding. Mol Simul 48(4):330\u2013341. https:\/\/doi.org\/10.1080\/08927022.2021.2015068","journal-title":"Mol Simul"}],"container-title":["Molecular Diversity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11030-024-10808-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11030-024-10808-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11030-024-10808-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T12:06:49Z","timestamp":1734610009000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11030-024-10808-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,23]]},"references-count":76,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["10808"],"URL":"https:\/\/doi.org\/10.1007\/s11030-024-10808-w","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-3327280\/v1","asserted-by":"object"}]},"ISSN":["1381-1991","1573-501X"],"issn-type":[{"value":"1381-1991","type":"print"},{"value":"1573-501X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,23]]},"assertion":[{"value":"5 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or nonfinancial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}